Dr Ioannis Vasiliadis

Qualifications

MD, PhD, FESC

GMC number: 7418836

Practising since: 2000

Specialties

Cardiology

Consultation times

  • Thursday PM
  • Overview
Book online today Enquire now

Or call us on

0300 131 1429

About

Dr Ioannis Vasiliadis joined Hereford County Hospital and Worcester Royal Hospital NHS Foundation Trust as a consultant interventional cardiologist in August 2018.

He has trained in interventional cardiology at Onassis Cardiac Surgery in Athens Greece  and Royal Free Hospital in London-UK. His scope or practice includes all aspects of general cardiology including cardiovascular prevention, diagnosis and treatment of hypertension (high blood pressure), hyperlipidaemia (raised cholesterol), heart failure(heart muscle disease) including chemotherapy induced cardiomyopathy, valvular heart disease, perioperative risk assessment, cardiovascular risk assessment  and arrhythmia(disturbances of heart rhythm). He subspecialises in interventional cardiology including coronary angiography, coronary angioplasty/stent insertion, right heart catheterisation and intravascular physiology and imaging. He also regularly consults patients presenting with symptoms of chest pain, shortness of breath, palpitations, heart murmurs, dizzy spells and blackouts.   He has conducted formal research in the area of Heart Failure and completed his PhD thesis on Gene polymorphism in Heart Failure. He is Fellow of European Society of Cardiology (FESC)

Locations Dr Ioannis Vasiliadis works with

Related experience

Research

  • Publications
  • Percutaneous coronary intervention rates and associated independent predictors for progression of non-target lesions in patients with diabetes mellitus after drug-eluting stent implantation. Vasiliadis Ioannis, Christophides Theodoros, Androulakis Emmanuel, Kolovou Genovefa. 01/06/2015.Journal title Angiology
  • Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance. Kolovou G, Vasiliadis I, Gontoras N, Kolovou V, Hatzigeorgiou G. 01/04/2015  Cardiovasc Ther.
  • Sudden Cardiac Death And Diabetes Mellitus. Vasiliadis I, Kolovou G, Mavrogeni S, Nair DR, Mikhailidis DP. 01/07/2014  J Diabetes Complications
  • Gene polymorphisms and thyroid function in patients with heart failure. Vasiliadis I, Kolovou G, Kolovou V, Giannakopoulou V, Boutsikou M, Katsiki N, Papadopoulou E, Mavrogeni S, Sorontila K, Pantos C, Cokkinos DV. 01/02/2014.Endocrine
  • Acute Cardiotoxic Effects of Adjuvant Trastuzumab Treatment.I Vasiliadis,V Kolovou, G Kolovou. 01/11/2014  Angiology.
  • Cardiotoxicity and Cancer Therapy.I Vasiliadis, G Kolovou, D P Mikhailidis. 01/05/2014. Angiology
  • A 6-month follow-up of intermittent Levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, Cokkinos DV. J Card Fail. 2007;13(7):556-9
  • Stress testing response in women heterozygous for familial hypercholesterolemia.Kolovou GD, Damaskos DS, Anagnostopoulou KK, Salpea KD, Dritsas A, Giannakopoulou V, Vasiliadis IK, Cokkinos DV. Int J Cardiol 2007;122(1):96-7.
  • Simvastatin: two decades in a circle. Kolovou GD, Katerina Anagnostopoulou, Ioannis Vasiliadis, Cokkinos DV. Cardiovasc Ther 2008;26(2):166-78.
  • High plasma adiponectin is related to low functional capacity in patients with chronic heart failure.. Laoutaris ID, Vasiliadis IK, Dritsas A, Mavrogeni S, Kallistratos MS, Manginas A, Chaidaroglou A, Degiannis D, Panagiotakos DB, Cokkinos DV. Int J Cardiol. 2010 Oct 8;144(2):230-1
  • Apolipoprotein E gene polymorphism and obesity status in middle-age men with coronary heart disease. G Kolovou, K Anagnostopoulou, P Kostakou, V Giannakopoulou, C Mihas, G Hatzigeorgiou, I Vasiliadis, D MIkhailidis D Cokkinos. In Vivo. 2009 Jan-Feb;23(1):33-9.
  • Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome. Kolovou G, Stamatelatou M, Anagnostopoulou K, Kostakou P, Kolovou V, Mihas C, Vasiliadis I, Diakoumakou O, Mikhailidis DP, Cokkinos DV. Open Cardiovasc Med J 2010;4:14-9.
  • Effects of Estrogens on Atherogeniiss.. Kolovou G, Giannakopoulou V, Vasiliadis Y,Bilianou H. Curr Vasc Pharmacol. 2011 Mar;9(2):244-57.
  • Ideal lipid profile and genes for an extended life span. Kolovou G, Kolovou V, Vasiliadis I, Wierzbicki AS, Mikhailidis DP. Curr Opin Cardiol 2011;26(4):348-55.
  • The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease. Kolovou G, Vasiliadis I, Kolovou V, Karakosta A, Mavrogeni S, Papadopoulou E, Papamentzelopoulos S, Giannakopoulou V, Marvaki A, Degiannis D, Bilianou H. Lipids Health Dis 2011;10:156
  • Aberrant left internal thoracic artery origin from the extrascalenic part of the subclavian artery. Andreou AY, Iakovou I, Vasiliadis I, Psathas C, Prokovas E, Pavlides G. Exp Clin Cardiol 2011;16(2):62-4.
  • Complex coronary artery anatomy in a patient with prolapsing left atrial myxoma. Andreou AY, Iakovou I, Dimopoulos AK, Karatasakis G, Anastasiou P, Vasiliadis I, Pavlides G. Herz 2012;37(3):342-346.
  • CYP8A1 Gene Polymorphisms and Left Main Coronary Artery Disease. Bousoula E, Kolovou V, Vasiliadis I, Karakosta A, Xanthos T, Johnson EO, Skandalakis P, Kolovou GD. Angiology. 2012 Aug;63(6):461-5.
  • Cholesteryl Ester Transfer Protein and ATP-Binding Cassette Transporter A1 Genotype Alter the Atorvastatin and Simvastatin Efficacy: Time for Genotype-Guided Therapy? Kolovou G, Kolovou V, Mihas C, Giannakopoulou V, Vasiliadis I, Boussoula E, Kollia A, Boutsikou M, Katsiki N, Mavrogeni S. Angiology. 2013 May;64(4):266-72.
  • The Frequency of 4 Common Gene Polymorphisms in Nonagenarians, Centenarians, and Average Life Span Individuals.Kolovou G, Kolovou V, Vasiliadis I, Giannakopoulou V,Mihas C, Bilianou H, Kollia A, Papadopoulou E, Marvaki A, Goumas G, Kalogeropoulos P, Limperi S, Katsiki N, Mavrogeni S. Angiology. 2014 Mar;65(3):210-5.
  • Common Variants of Apolipoprotein E and Cholesteryl Ester Transport Protein Genes in Male Patients With Coronary Heart Disease and Variable Body Mass Index. Kolovou GD, Panagiotakos DB, Kolovou V, Vasiliadis I, Giannakopoulou V, Diakoumakou O, Katsiki N, Mavrogeni S. Angiology 2015 Feb;66(2):169-73
  • Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.Kolovou G, Ragia G, Kolovou V, Mihas C, Katsiki N, Vasiliadis I, Mavrogeni S, Vartela V, Tavridou A, Manolopoulos VG.Open Cardiovasc Med J. 2014 Feb 7;8:12-7.
  • Study of common variants of the apolipoprotein E and lipoprotein lipase genes in patients with coronary heart disease and variable body mass index.Kolovou GD, Kolovou V, Panagiotakos DB, Vasiliadis I, Giannakopoulou V, Kostakou PM, Vartela V, Mavrogeni S. Hormones (Athens). 2015 Jul;14(3):376-82. doi: 10.14310/horm.2002.1572.
  • CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin.Kolovou G, Kolovou V, Ragia G, Mihas C, Diakoumakou O, Vasiliadis I, Mavrogeni S, Vartela V, Manolopoulos VG.Genet Mol Biol. 2015 May;38(2):129-37. doi: 10.1590/S1415-4757382220140239. Epub 2015 May 1.PMID: 26273214
  • Efficacy and safety of biodegradable polymer biolimus a9-eluting stent vs. durable polymer everolimus-eluting stent in patients with coronary artery disease.T Christophides, I Vasiliadis, E Androulakis, S Koganti, R Rakhit. Royal Free Hospital, Cardiology, London, United Kingdom
  • Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.Kolovou V, Diakoumakou O, Papazafiropoulou AK, Katsiki N, Fragopoulou E, Vasiliadis I, Degiannis D, Duntas L, Antonopoulou S, Kolovou G.Open Cardiovasc Med J. 2018 Jul 31;12:59-70.

Memberships

  • Fellow of European Society of Cardiology (FESC)
  • Member of British Cardiovascular Intervention Society (BCIS)

Other posts held

  • Consultant Cardiologist at Hereford County Hospital

Insurers Dr Ioannis Vasiliadis works with

Dr Ioannis Vasiliadis works with the following private medical insurance providers:

  • Aetna
  • Aviva Health
  • AXA Health
  • AXA - Global Healthcare
  • Bupa
  • Bupa Global
  • Bupa On Demand
  • Cigna
  • Cigna International
  • Healix
  • Healix Healthcare
  • Vitality Health (Pru Health)
  • WPA
  • Westfield Health WPA

Declaration

Dr Ioannis Vasiliadis does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Dr Ioannis Vasiliadis does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Dr Ioannis Vasiliadis does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.